MediciNova gains approval to present abstract on ALS therapy MN-166
Category: #Health  By Paroma Bhattacharya  Date: 2019-07-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

MediciNova gains approval to present abstract on ALS therapy MN-166

The company CMO, Kazuko Matsuda will present the abstract titled “Interaction (nonuniformity) of ALS Progression and the Efficacy of MN-166 (ibudilast)” at the 30th International Symposium.

MediciNova, Inc., a biopharmaceutical organization focused on developing small-molecule therapeutics for the treatment of diseases that lack clinical cure, recently announced that an abstract concerning its completed clinical trial of MN-166 (ibudilast) in ALS has been approved for presentation at the 30th International Symposium on Amyotrophic Lateral Sclerosis/Motor Neurone Disease (ALS/MND), scheduled in Perth, Australia. 

Speaking on the move, Dr. Yuichi Iwaki, President and Chief Executive Officer, MediciNova, said that the company is delighted to present its research on ALS at the 30th International Symposium on ALS/MND. He said that their firm will use this opportunity to share its study and results with all the ALS/MND researchers, patients and clinicians who initially laid the foundation of design and implementation of its upcoming ALS trial.  

Reportedly, the pilot was a double-blind, randomized, placebo-controlled study which involved six-month treatment period accompanied by a six-month open-label extension. In collaboration with Carolinas Neuromuscular/ALS-MDA Center’s Director, Dr. Benjamin Rix Brooks, MediciNova offered patients a dose of 60 mg of MN-166 per day in both early and last stage of ALS.

For the record, amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that damages nerve cells in the spinal cord and the brain. The nerves lose the ability to prompt specific muscles, which makes the muscles weak. The condition affects voluntary movement of patients which results to complete paralysis in the later stages. Generally, an ALS patient’s life expectancy lasts between 2-5 years.

However, MN-166 (ibudilast)'s neuroprotective and anti-neuroinflammatory actions provide the rationale for treatment of ALS, progressive MS (multiple sclerosis) and other neurological diseases like glioblastoma (GBM), and substance addiction/abuse. These actions have also been demonstrated in preclinical and clinical studies, cite reports.

Source Credit: https://investors.medicinova.com/news-releases/news-release-details/medicinova-announces-mn-166-ibudilast-als-abstract-accepted-4



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Bio-Thera Solutions commences Phase 1 study for Simponi® biosimilar
Bio-Thera Solutions commences Phase 1 study for Simponi® biosimilar
By Paroma Bhattacharya

Bio-Thera Solutions, a China based pharmaceutical company, has reportedly announced the start of dosing of its first batch of healthy volunteers in order to compare the safety and pharmacokinetics of BAT2506, proposed ...

Mevion & C-RAD integrate for better treatment in proton therapy
Mevion & C-RAD integrate for better treatment in proton therapy
By Paroma Bhattacharya

  • C-RAD to offer a specific version of Catalyst System named Catalyst PT in proton therapy.
  • Catalyst PT would be especially used for thoracic tumor i...

Amazon plans to open a brick-and-mortar liquor store in San Francisco
Amazon plans to open a brick-and-mortar liquor store in San Francisco
By Paroma Bhattacharya

  • The company is looking to launch a liquor shop in San Francisco for various alcoholic beverages.
     
  • Application for a liquor license and...